Lightning "megaflash" stretching 515 miles long is recognized as new world record
The flash — dubbed a "megaflash," or a single continuous long horizontal flash that can initiate up to hundreds of cloud-to-ground strikes — happened on Oct. 22, 2017, according to a research report published in the Bulletin of the American Meteorological Society. While the storm that day had previously been analyzed by scientists, new satellite technology recently documented the megaflash exceeding 500 miles.
The previous world record recognized by the World Meteorological Organization was a megaflash on April 29, 2020, extending 477 miles across the southern United States and the Gulf of Mexico, the researchers said.
While the 2017 megaflash may be the longest in horizontal distance, it did not have the longest duration. Researchers estimated that it lasted just over 7 seconds. The current WMO-recognized record for longest duration megaflash occurred over Argentina and Uruguay in June 2020 and was about 17 seconds.
Researchers hope the technology that identified the 2017 megaflash will continue to help them evaluate more storms.
"We're excited to see what kinds of lightning come out of this new work, and especially as technology improves and we are able to get satellites and other parts of the world, then we'll be able to expand towards the eventual vision of providing global coverage of lightning," said Michael Peterson, the report's lead author and a senior research scientist at Georgia Tech Research Institute.
New records are likely to continue to be recognized, said Randall Cerveny, the weather and climate extremes rapporteur for WMO.
"It is likely that even greater extremes still exist, and that we will be able to observe them as additional high-quality lightning measurements accumulate over time," he said in a statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
BEDFORD, Mass., August 06, 2025--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit View source version on Contacts Stoke Media & Investor Contacts: Dawn KalmarChief Communications Officerdkalmar@ 781-303-8302 Doug SnowDirector, Communications & Investor RelationsIR@ 508-642-6485
Medscape
41 minutes ago
- Medscape
Dato-DXd Shows Potential in Treating Lung Adenocarcinoma
This transcript has been edited for clarity. I'm Mark Kris, from Memorial Sloan Kettering, continuing a discussion about antibody-drug conjugates, or ADCs, and in this case, datopotamab deruxtecan, or Dato-DXd. This agent combines an anti-TROP2 antibody with a potent topoisomerase I inhibitor. It has had activity in a number of diseases, but the topic today is lung cancer. There has been a phase 3 randomized trial already. It's shown, compared to docetaxel, an improved rate of response by about 10% or so. It showed a small improvement in disease-free survival and about a 1-month improvement in overall survival over docetaxel. I think what this trial shows is that it clearly is an active agent, and I think it's useful to us for patients with adenocarcinoma, giving us an additional line of therapy. It would be a real judgment call when a patient needs a new line of therapy whether to give docetaxel or the Dato-DXd first. The drug is not yet approved for lung cancer but is obviously in the approval process now. The other thing noted in that phase 3 trial was that there was very limited activity. In fact, [there was] less activity than docetaxel in patients with squamous cell cancers. Clearly, that activity is largely limited to the adenocarcinoma patients, and I think that's where, if approved, it will finally be useful. The companion paper in the Journal of Clinical Oncology reports on the use of Dato-DXd in patients whose tumors have oncogenic drivers. They found a higher-than-expected response rate. It was in the twenties in an unselected population, but in the patients with EGFR mutations it was 36%, and in patients with ALK rearrangements in their tumors, it was 44%. I think this may be the place where it will be most useful. In 2025, we still don't have a therapy beyond standard chemotherapy after progression on osimertinib, and this may be a useful drug in that place. Again, it's useful in adenocarcinoma. To summarize, Dato-DXd is a drug in the regulatory approval process that clearly has activity in an unselected population of patients with adenocarcinoma. It's roughly comparable and slightly better than docetaxel. However, it's less effective than docetaxel in a squamous population. In addition, at least in other trials, it has shown some activity and perhaps even more activity in patients with drivers like EGFR or ALK .It may have some usefulness there. I think we're fortunate to have more new agents. We're fortunate to be able to make more choices to match drugs and side effects to specific patient characteristics and specific patient preferences. Once again, our job is better but it's hard. Clearly, the harder we work, the better we're going to make the course of illness for our patients.
Washington Post
42 minutes ago
- Washington Post
Trump once hailed mRNA vaccines as a 'medical miracle.' Now RFK Jr. is halting advancement
WASHINGTON — President Donald Trump hailed as a 'medical miracle' the mRNA vaccines developed to combat the deadly COVID-19 pandemic in 2020. Now, his health secretary Robert F. Kennedy Jr. , is effectively halting the vaccine technology's advancement. Kennedy announced Tuesday that the federal government is canceling $500 million worth of mRNA research development contracts, putting an end to U.S.-backed hopes for the vaccine technology to prevent future pandemics, treat cancer or prevent flu infections.
